Williams Financial LLC Invests $3.66 Million in Pfizer Inc. (NYSE:PFE)

Williams Financial LLC acquired a new position in Pfizer Inc. (NYSE:PFE) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 132,794 shares of the biopharmaceutical company’s stock, valued at approximately $3,655,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of PFE. Olistico Wealth LLC acquired a new position in shares of Pfizer in the 2nd quarter worth $25,000. Creekmur Asset Management LLC acquired a new position in shares of Pfizer in the 4th quarter worth $32,000. Trivant Custom Portfolio Group LLC grew its holdings in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the last quarter. Tennessee Valley Asset Management Partners acquired a new position in shares of Pfizer in the 4th quarter worth $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new position in shares of Pfizer in the 4th quarter worth $37,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE traded down $0.41 during mid-day trading on Friday, hitting $28.30. 50,332,917 shares of the company’s stock traded hands, compared to its average volume of 37,428,500. The firm has a 50 day moving average of $28.75 and a two-hundred day moving average of $27.91. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $160.36 billion, a price-to-earnings ratio of -471.67, a price-to-earnings-growth ratio of 1.00 and a beta of 0.69. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $37.19.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.67 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.68 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.94%. Pfizer’s dividend payout ratio (DPR) is -2,800.00%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, July 31st. UBS Group upped their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. BMO Capital Markets reissued an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Barclays upped their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.